{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:55Z","timestamp":1792801375170,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.clinthera.2006.08.004","type":"journal-article","created":{"date-parts":[[2006,9,19]],"date-time":"2006-09-19T11:16:16Z","timestamp":1158664576000},"page":"1065-1078","source":"Crossref","is-referenced-by-count":242,"title":["A review of the receptor-binding and pharmacokinetic properties of dopamine agonists"],"prefix":"10.1016","volume":"28","author":[{"given":"Trond","family":"Kvernmo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"H\u00e4rtter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.08.004_bib1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med."},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.08.004_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","article-title":"An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines","volume":"56","author":"Olanow","year":"2001","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.08.004_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.08.004_bib4","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.08.004_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","article-title":"A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease","volume":"9","author":"Olanow","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson's disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.08.004_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","article-title":"Range of neuropsychiatric disturbances in patients with Parkinson's disease","volume":"67","author":"Aarsland","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2006.08.004_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/ajp.149.4.443","article-title":"Depression and Parkinson's disease: A review","volume":"149","author":"Cummings","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.08.004_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bmj.320.7245.1287","article-title":"Depression in Parkinson's disease","volume":"320","author":"Allain","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.08.004_bib10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.08.004_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","article-title":"Pergolide use in Parkinson disease is associated with cardiac valve regurgitation","volume":"63","author":"Baseman","year":"2004","journal-title":"Neurology"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2006.08.004_bib12","first-page":"S79","article-title":"Cardiac valve abnormalities in patients with Parkinson's disease","volume":"20","author":"Reuter","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20931","article-title":"Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists","author":"Kim","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"Kaye","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2006.08.004_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/j.1552-4604.1997.tb04330.x","article-title":"Steady-state pharmacokinetic properties of pramipexole in healthy volunteers","volume":"37","author":"Wright","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib16","first-page":"841","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers","volume":"80","author":"Andreotti","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.08.004_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.wnf.0000168581.97083.9c","article-title":"Pergolide: Multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease","volume":"28","author":"Thalamas","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib19","unstructured":"Available at: http:\/\/www.cyp450.no [in Norwegian]. Accessed June 1, 2006."},{"key":"10.1016\/j.clinthera.2006.08.004_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0922-4106(95)90013-6","article-title":"Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors","volume":"290","author":"Mierau","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1353-8020(00)00062-6","article-title":"The use of pramipexole in Parkinson's disease: Are its actions D(3) mediated?","volume":"7","author":"Guttman","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2006.08.004_bib23","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/00004850-199707003-00002","article-title":"The mesolimbic dopamine system as a target for rapid antidepressant action","volume":"12","author":"Willner","year":"1997","journal-title":"Int Clin Psychopharm"},{"key":"10.1016\/j.clinthera.2006.08.004_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0006-8993(02)03396-6","article-title":"Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: Role of D3 and not D2 receptors","volume":"955","author":"Joyce","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2006.08.004_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of mono aminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide","volume":"61","author":"van Camp","year":"2003","journal-title":"Neurology"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2006.08.004_bib27","first-page":"S84","article-title":"Valvular heart disease associated with low cumulative dose of pergolide in the patient with Parkinson's disease","volume":"20","author":"Chung","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20887","article-title":"Valvular heart disease in Parkinson's disease vs. controls: An echocardio graphic study","author":"Peralta","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib30","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1055\/s-2007-1017756","article-title":"Dopaminagonisten im vergleich","volume":"25","author":"Brecht","year":"1998","journal-title":"Akt Neurologie"},{"key":"10.1016\/j.clinthera.2006.08.004_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","article-title":"Agonism at 5-HT2B receptors is not a class effect of the ergolines","volume":"513","author":"Jahnichen","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00002826-200305000-00001","article-title":"Fibrosis associated with dopamine agonist therapy in Parkinson's disease","volume":"26","author":"M\u00fcller","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib33","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(04)16369-1","article-title":"Pergolide in Parkinson's disease: Time for a change?","volume":"363","author":"Grosset","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.08.004_bib34","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0024-3205(97)00126-4","article-title":"D1 dopamine receptor activity of anti-parkinsonian drugs","volume":"60","author":"Fici","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2006.08.004_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00002826-200109000-00001","article-title":"Choosing dopamine agonists in Parkinson's disease","volume":"24","author":"Tan","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib36","first-page":"CD001519","article-title":"Cabergoline versus bromocriptine for levodopa-induced complications in Parkin son's disease","volume":"1","author":"Clarke","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2006.08.004_bib37","first-page":"407","article-title":"Dopamine agonists","author":"Stacy","year":"2003"},{"key":"10.1016\/j.clinthera.2006.08.004_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2006.08.004_bib39","series-title":"Bromocriptine [SPC]","year":"2003"},{"key":"10.1016\/j.clinthera.2006.08.004_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","article-title":"Fibrotic valvular heart disease subsequent to bromocriptine treatment","volume":"10","author":"Serratrice","year":"2002","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.clinthera.2006.08.004_bib41","first-page":"1211","article-title":"Assessment of potential interactions between dopamine receptor ago nists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen","volume":"25","author":"Wynalda","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2006.08.004_bib42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/clpt.1990.95","article-title":"Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine","volume":"47","author":"Nelson","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clpt.2003.12.012","article-title":"St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism","volume":"75","author":"Tannergren","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2006.08.004_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clpt.2003.09.014","article-title":"St John's wort induces both cytochrome P450 3A4-catalyzed sul foxidation and 2C19-dependent hydroxylation of omeprazole","volume":"75","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.2003.02049.x","article-title":"Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females","volume":"57","author":"Wenk","year":"2004","journal-title":"Brj Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib46","series-title":"Cabergoline [SPC]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.004_bib47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002512-200320110-00006","article-title":"Cabergoline, pramipexole and ropinirole used as monotheraphy in early Parkinson's disease: An evidence-based comparison","volume":"20","author":"Inzelberg","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2006.08.004_bib48","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1136\/hrt.2004.036236","article-title":"Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease","volume":"90","author":"Townsend","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2006.08.004_bib49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00702-005-0289-1","article-title":"Retrospective evaluation of cardiopulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline","volume":"112","author":"Dhawan","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinthera.2006.08.004_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1254\/jphs.FP0050711","article-title":"Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease","volume":"100","author":"Nakatsuka","year":"2006","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2006.08.004_bib51","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/mds.10250","article-title":"Cabergoline plasma concentration is increased during concomitant treatment with itraconzole","volume":"17","author":"Christensen","year":"2002","journal-title":"Mov Disord"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2006.08.004_bib52","first-page":"S123","article-title":"Beneficial interactions between grapefruit juice and dopamine agonists in patients with Parkinson's disease","volume":"20","author":"Nagai","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clpt.2004.06.007","article-title":"Effect of St John's wort on imatinib mesylate pharmacokinetics","volume":"76","author":"Frye","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib54","series-title":"Pergolide [SPC]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.08.004_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mds.20724","article-title":"Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study","volume":"21","author":"Oertel","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1176\/ajp.153.3.311","article-title":"Newer antidepressants and the cytochrome P450 system","volume":"153","author":"Nemeroff","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.08.004_bib57","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/mds.20813","article-title":"Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide","volume":"21","author":"Chung","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib58","doi-asserted-by":"crossref","first-page":"P79","DOI":"10.1016\/j.clpt.2003.11.300","article-title":"Pharmacokinetic study on the interaction between cabergoline and clarithromycin in healthyvolunteers and patients with Parkinson's disease","volume":"75","author":"Nomoto","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib59","series-title":"Pramipexole [SPC]","year":"2006"},{"key":"10.1016\/j.clinthera.2006.08.004_bib60","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jnnp.72.6.713","article-title":"Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: A randomised, double blind, placebo controlled multicentre study","volume":"72","author":"Pogarell","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2006.08.004_bib61","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkin son's disease: Results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2006.08.004_bib62","first-page":"182","article-title":"The population pharmacokinetics of pramipexole in Parkinson's dis ease patients","volume":"61","author":"Wright","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib63","series-title":"Ropinirole [SPC]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.08.004_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002280050632","article-title":"Lack of pharmacokinetic interaction between ropini role and theophylline in patients with Parkinson's disease","volume":"55","author":"Thalamas","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib65","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/cp.1999.v66.103404001","article-title":"Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy","volume":"66","author":"Lame","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib66","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1345\/aph.10364","article-title":"Warfarin and ropinirole interaction","volume":"35","author":"Bair","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2006.08.004_bib67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future","volume":"25","author":"Ingelman-Sundberg","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2006.08.004_bib68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0009-9236(95)90154-X","article-title":"Association between the oxidative polymorphism and early onset of Parkinson's disease","volume":"57","author":"Agundez","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.08.004_bib69","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20051","article-title":"CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease","volume":"55","author":"Elbaz","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib70","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ana.20143","article-title":"Further evidence that interactions between CYP2D6 and pesti cide exposure increase risk for Parkinson's disease","volume":"55","author":"Deng","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2006.08.004_bib71","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0022-510X(97)00179-2","article-title":"The association between polymorphisms in the cy tochrome P-450 2D6 gene and Parkinson's disease: A case-control study and meta-analysis","volume":"153","author":"McCann","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinthera.2006.08.004_bib72","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/CCLM.2000.136","article-title":"Genotyping of CYP2D6 in Parkinson's disease","volume":"38","author":"Stefanovic","year":"2000","journal-title":"Clin Chem Lab Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T01:36:27Z","timestamp":1529544987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0149291806001846"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.08.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}